Quick Answer — For Those Who Need It Right Now
If your child or family member has been diagnosed with Spinal Muscular Atrophy and you are searching for the most advanced treatment available anywhere in the world, the United States is where that treatment exists. The FDA has approved gene therapies for SMA that are available right now at leading US medical centres. International patients are eligible to access these treatments through MediPocket USA’s physician-led medical concierge service.
What Is Spinal Muscular Atrophy (SMA)?
Spinal Muscular Atrophy is a rare, progressive genetic disease that destroys the motor neurons — the nerve cells that control movement — in the spinal cord. As these neurons die, the muscles they control weaken progressively, affecting a patient’s ability to walk, sit, swallow, and eventually breathe.
It is caused by a mutation or deletion in the SMN1 gene — the gene responsible for producing Survival Motor Neuron (SMN) protein. Without sufficient SMN protein, motor neurons cannot function and begin to deteriorate.
Spinal Muscular Atrophy is a rare genetic condition that causes progressive muscle weakness, affecting the nerves that control movement and making everyday activities like holding up the head, swallowing, sitting, or walking difficult or impossible without treatment. In the United States, SMA affects an estimated 10,000 to 25,000 people, with about 500 new cases diagnosed each year.
Before 2016, there was no treatment for SMA at all. Families received a diagnosis and a prognosis, and very little else. That reality has changed dramatically — and nowhere more so than in the United States.
The Four Types of SMA — Understanding the Spectrum
SMA presents across a broad spectrum of severity, classified by age of onset and motor milestone achievement:
SMA Type 1 (Werdnig-Hoffmann Disease) The most severe form. Untreated Type 1 disease accounts for 60% of cases and is the leading genetic cause of mortality in babies, resulting in a short life expectancy of 2 years for 90% of untreated patients. Symptoms appear within the first 6 months of life. Infants cannot sit without support.
SMA Type 2 Intermediate severity. Children can sit but cannot stand or walk independently. Onset typically between 6 and 18 months. Progressive scoliosis and respiratory complications develop over time.
SMA Type 3 (Kugelberg-Welander Disease) Milder form. Children achieve the ability to stand and walk, though this is often lost over time. Onset after 18 months.
SMA Type 4 Adult onset. Mild muscle weakness, typically beginning in early adulthood. Least severe form.
Why the type matters for treatment: Each type has different eligibility criteria for the gene therapies currently available and in development. The breakthrough in 2026 is that treatment is no longer restricted to only infants — older patients now have access to approved gene therapy for the first time in medical history.
The Treatment Landscape Before Gene Therapy — What Changed
Until 2016, SMA had no approved treatment anywhere in the world. Families managed symptoms — respiratory support, physiotherapy, nutritional intervention — but could not slow or stop the disease itself.
Three approvals changed everything:
2016 — Nusinersen (Spinraza) The first-ever approved therapy for SMA. An antisense oligonucleotide delivered via spinal injection that promotes SMN protein production from the SMN2 backup gene. Requires ongoing injections — not a one-time treatment.
2019 — Onasemnogene Abeparvovec (Zolgensma) A landmark one-time intravenous gene therapy approved by the FDA for patients under 2 years of age. A one-time intravenous injection introducing the SMN1 transgene into motor neurons using an adeno-associated viral vector to promote SMN protein expression and replace the non-functional SMN1 gene, with the hope to slow down disease progression.
2020 — Risdiplam (Evrysdi) The first orally deliverable therapy for SMA — a daily liquid medication that can be taken at home, promoting SMN protein production.
These three approvals represented the most dramatic transformation in the treatment of any rare genetic disease in modern medical history.
But the most significant development of all came in 2026.
The 2026 Breakthrough: FDA Approves Itvisma — Gene Therapy for Patients 2 Years and Older
This is the most important development in SMA treatment since Zolgensma was approved in 2019.
The US Food and Drug Administration approved Itvisma (onasemnogene abeparvovec-brve) for the treatment of Spinal Muscular Atrophy in adult and paediatric patients 2 years of age and older with confirmed mutation in the survival motor neuron 1 (SMN1) gene. Itvisma is an adeno-associated virus (AAV) vector-based gene therapy.
This is a seismic shift. Previously, gene therapy for SMA was only available for patients under 2 years of age. Older children, teenagers, and adults with SMA had no access to gene replacement therapy — they were managing the disease, not addressing its root cause.
The approval makes the treatment the only replacement therapy available for a broad range of patients with the disease, and it may improve their motor function, thereby potentially reducing the need for continuous treatment.
What makes Itvisma different from Zolgensma?
The direct administration of Itvisma into the cerebrospinal fluid surrounding the spinal cord — the site of action — allows for delivery to motor neurons with a lower dose of vector, without the need to adjust for the patient’s body weight.
Instead of an intravenous infusion, Itvisma is delivered intrathecally — directly into the fluid surrounding the spinal cord. This targeted delivery means a lower viral dose is required, making it safer and more effective for older, larger patients who would have required impractically high doses through an IV route.
According to John W. Day, MD, director of the Division of Neuromuscular Medicine at Stanford University School of Medicine — “The FDA’s approval of intrathecal onasemnogene abeparvovec is a game-changing advance, expanding the use of transformational gene replacement therapy for SMA across age groups.”
High-Dose Spinraza — The Second 2026 Approval
Itvisma was not the only landmark approval in early 2026.
On March 30, 2026, the FDA also approved high-dose Spinraza, which could prevent SMA progression sooner.
This expanded formulation of the original Spinraza treatment is designed to deliver a more powerful dose of SMN protein-promoting therapy earlier in the disease course — potentially halting progression before significant motor neuron loss has occurred.
For patients who are not candidates for gene therapy, or who choose a non-surgical route, high-dose Spinraza represents a meaningful advancement in the management arm of SMA treatment.
What Is Next-Generation Gene Therapy for SMA? The CHARISMA Trial
Beyond what is already approved, the pipeline for SMA gene therapy in 2026 is extraordinary.
GEMMABio announced the first patient has been dosed in the Phase 1/2 CHARISMA clinical trial of GB221, an investigational next-generation gene therapy for SMA Type 1. The CHARISMA trial is the first clinical evaluation of a next-generation gene therapy for SMA1 delivered directly to the cerebrospinal fluid by intracisterna-magna (ICM) injection.
This next-generation approach targets patients with SMA Type 1 — the most severe and life-threatening form — with a delivery method designed to maximise reach to the motor neurons most critically affected. It represents the frontier of what is possible beyond current approvals, and it is actively enrolling patients right now.
For families with SMA Type 1 infants who have not yet had sufficient time to benefit from approved therapies, or whose disease is progressing despite current treatment — this trial represents a genuinely new option that did not exist even a year ago.
Who Qualifies for SMA Gene Therapy in the USA?
For Itvisma (FDA Approved, 2025/2026): → Patients aged 2 years and older → Confirmed SMN1 gene mutation on genetic testing → Diagnosis across the SMA spectrum — Types 1, 2, 3, and 4 → No previous treatment exclusions across all types → International patients are eligible — no US residency required → Treatment available at specialised neuromuscular centres across the US
For Zolgensma (FDA Approved, 2019): → Patients under 2 years of age → Confirmed bi-allelic SMN1 gene deletion or mutation → Pre-symptomatic diagnosis increasingly common through newborn screening programmes → Most effective when administered before significant motor neuron loss occurs
For the CHARISMA Trial (GB221 — Currently Enrolling): → SMA Type 1 patients — specific eligibility criteria per trial protocol → International patients may be eligible — MediPocket coordinates eligibility assessment
For Risdiplam (Evrysdi) and High-Dose Spinraza: → Broader eligibility across SMA types and age groups → Oral or intrathecal administration respectively → Used independently or alongside gene therapy in some protocols
Frequently Asked Questions About SMA Gene Therapy in the USA
Q: Can my child receive gene therapy for SMA if we are not from the United States? Yes. The FDA-approved therapies are available to international patients at US medical centres. There is no citizenship or residency requirement. MediPocket coordinates the entire access process for international families.
Q: Is SMA gene therapy a cure? Gene therapy for SMA replaces the non-functional SMN1 gene and restores SMN protein production — addressing the root genetic cause of the disease. Clinical outcomes show it can halt or significantly slow progression, and many patients achieve motor milestones previously considered impossible. Whether it constitutes a complete cure depends on the patient’s age, disease stage, and type — outcomes are most dramatic when treatment is administered early.
Q: My child was diagnosed with SMA Type 2 and is 5 years old. Is gene therapy still an option? With the approval of Itvisma in 2025/2026 — yes. Gene therapy is now approved for patients aged 2 and older across all SMA types with confirmed SMN1 mutation. This is a direct result of the 2026 FDA approval that did not exist for older children previously.
Q: How much does SMA gene therapy cost in the USA? Gene therapy for SMA is among the most expensive treatments in medicine. However, clinical trial participation may cover significant treatment costs. MediPocket negotiates pricing transparency before any family commits to travelling. We clarify exact costs, trial coverage, and out-of-pocket expectations before you make any decision.
Q: What is the difference between Zolgensma and Itvisma? Both are gene replacement therapies targeting the SMN1 gene. Zolgensma is administered intravenously and approved for patients under 2 years. Itvisma is administered intrathecally (into the cerebrospinal fluid) and approved for patients aged 2 and older — making it suitable for a dramatically broader patient population.
Q: Can adults with SMA access gene therapy? Yes — for the first time. The 2026 approval of Itvisma explicitly covers adult patients with confirmed SMN1 mutation. This is historically significant. Prior to this approval, adults with SMA had no access to gene replacement therapy anywhere in the world.
Q: Which US hospitals offer SMA gene therapy? Leading centres include Boston Children’s Hospital, Cincinnati Children’s Hospital, Stanford Children’s Health, Columbia University Irving Medical Centre, and Texas Children’s Hospital. MediPocket identifies the most appropriate institution based on the patient’s specific SMA type, age, and prior treatment history.
Why the USA Leads the World in SMA Treatment
The United States’ position as the global leader in SMA treatment is not coincidental. It is the product of specific structural advantages:
FDA Speed and Rigor Combined The FDA’s Breakthrough Therapy Designation, Rare Paediatric Disease designation, and Accelerated Approval pathways move transformative treatments from trial to patient faster than any regulatory body in the world — while maintaining the safety standards that make those approvals globally trusted.
NIH Funding at Unmatched Scale The US National Institutes of Health invests billions annually in rare disease research — the funding infrastructure behind every SMA breakthrough traces back to this ecosystem.
Neuromuscular Centres of Excellence US institutions have dedicated neuromuscular departments with the clinical volume, infrastructure, and specialist depth to handle complex SMA cases that most international hospitals simply haven’t encountered in sufficient numbers to develop equivalent expertise.
Newborn Screening Integration The US has integrated SMA into its newborn screening programmes — meaning many patients are now diagnosed before symptoms appear, making the window for most effective gene therapy treatment dramatically wider than in countries without early screening.
Clinical Trial Ecosystem The CHARISMA trial represents the first clinical evaluation of next-generation gene therapy for SMA1 delivered directly to the cerebrospinal fluid — and it is enrolling in the US right now. The pipeline behind currently approved treatments is deeper in the US than anywhere else.
How International Patients Access SMA Gene Therapy Through MediPocket USA
This is where the gap between knowing treatment exists and actually receiving it becomes real for most international families.
Accessing SMA gene therapy in the USA as a patient from India, Saudi Arabia, UAE, Singapore, Japan, or South Korea involves navigating a system built for American patients. Without the right guide, the process is overwhelming — and delays in SMA treatment are not neutral. Every week matters. Every month of untreated disease means motor neurons that cannot be recovered.
MediPocket USA exists precisely to close this gap.
Here is exactly what we do for SMA families:
✔ Physician-led case review — Dr. Priyanka Mathur and our medical team review your child’s genetic test results, clinical history, and current functional status within 48 hours of contact
✔ Treatment and trial matching — We identify whether Itvisma, Zolgensma, Risdiplam, high-dose Spinraza, or an active clinical trial is most appropriate for your specific case
✔ Institution coordination — We initiate direct contact with the neuromuscular team at the most appropriate US centre — Boston Children’s, Stanford, Cincinnati Children’s, or others — on your behalf
✔ Medical record preparation — Complete formatting, genetic report translation, and submission in the format required by the US institution
✔ Pricing transparency — Full cost breakdown negotiated and communicated before you commit to travelling
✔ Visa and travel coordination — Medical visa documentation, accommodation near the treating centre, and ground transportation
✔ On-ground support — MediPocket’s team supports you through every appointment, every decision, and every step of the treatment process while you are in the US
✔ Post-treatment follow-up — Once you return home, our physician team continues to monitor your child’s progress and coordinate with the US centre for ongoing care
The Window of Opportunity Is Real — and It Is Now
SMA is a disease where timing is everything. Motor neurons lost before treatment cannot be recovered. The earlier gene therapy is administered, the more function can be preserved — and in many cases, the more function is gained.
The 2026 approval of Itvisma has opened the window for thousands of older patients who had no gene therapy option before this year. But that window is only useful if families know it exists — and know how to walk through it.
If your child or family member has been diagnosed with SMA — in India, Saudi Arabia, Singapore, UAE, Japan, South Korea, or anywhere in the world — and you have been told that options are limited, or that gene therapy is not available where you are — this article is the beginning of a different conversation.
The treatment exists. The door is open. MediPocket will take you through it.
Start Your SMA Case Review Today
📩 Contact MediPocket USA — no forms, no commitment, just a direct conversation about your case.
Our physician-led team reviews every SMA enquiry personally and responds within 24 hours.
🌐 medipocketusa.com 💬 WhatsApp: +1 818 235 3291 📧 health@mymedipocket.com
One conversation. It costs you nothing. It could change everything.
